Clinical effectiveness of a patient decision aid to improve decision quality and glycaemic control in people with diabetes making treatment choices: a cluster randomised controlled trial (PANDAs) in general practice by Mathers, N.J. et al.
Clinical effectiveness of a patient
decision aid to improve decision quality
and glycaemic control in people with
diabetes making treatment choices:
a cluster randomised controlled trial
(PANDAs) in general practice
Nigel Mathers,1 Chirk Jenn Ng,2 Michael Joseph Campbell,3 Brigitte Colwell,1
Ian Brown,4 Alastair Bradley1
To cite: Mathers N, Ng CJ,
Campbell MJ, et al. Clinical
effectiveness of a patient
decision aid to improve
decision quality and
glycaemic control in people
with diabetes making
treatment choices: a cluster
randomised controlled trial
(PANDAs) in general practice.
BMJ Open 2012;2:e001469.
doi:10.1136/bmjopen-2012-
001469
▸ Prepublication history and
additional material for this
paper are available online. To
view these files please visit
the journal online
(http://dx.doi.org/10.1136/
bmjopen-2012-001469).
Received 3 July 2012
Accepted 1 October 2012
This final article is available
for use under the terms of
the Creative Commons
Attribution Non-Commercial
2.0 Licence; see
http://bmjopen.bmj.com
For numbered affiliations see
end of article
Correspondence to
Nigel Mathers;
n.mathers@sheffield.ac.uk
ABSTRACT
Objective: To determine the effectiveness of a patient
decision aid (PDA) to improve decision quality and
glycaemic control in people with diabetes making
treatment choices using a cluster randomised
controlled trial (RCT).
Design: A cluster RCT.
Setting: 49 general practices in UK randomised into
intervention (n=25) and control (n=24).
Participants: General practices Inclusion criteria:
>4 medical partners; list size >7000; and a diabetes
register with >1% of practice population. 191 practices
assessed for eligibility, and 49 practices randomised
and completed the study. Patients People with type 2
diabetes mellitus (T2DM) taking at least two oral
glucose-lowering drugs with maximum tolerated dose
with a glycosolated haemoglobin (HbA1c) greater than
7.4% (IFCC HbA1c >57 mmol/mol) or advised in the
preceeding 6 months to add or consider changing to
insulin therapy. Exclusion criteria: currently using
insulin therapy; difficulty reading or understanding
English; difficulty in understanding the purpose of the
study; visual or cognitive impairment or mentally ill. A
total of 182 assessed for eligibility, 175 randomised to
95 intervention and 80 controls, and 167 completion
and analysis.
Intervention: Brief training of clinicians and use of
PDA with patients in single consultation.
Primary outcomes: Decision quality (Decisional
Conflict Scores, knowledge, realistic expectations and
autonomy) and glycaemic control (glycosolated
haemoglobin, HbA1c).
Secondary outcomes: Knowledge and realistic
expectations of the risks and benefits of insulin therapy
and diabetic complications.
Results: Intervention group: lower total Decisional
Conflict Scores (17.4 vs 25.2, p<0.001); better
knowledge (51.6% vs 28.8%, p<0.001); realistic
expectations (risk of ‘hypo’, ‘weight gain’,
‘complications’; 81.0% vs 5.2%, 70.5% vs 5.3%,
26.3% vs 5.0% respectively, p<0.001); and were more
autonomous in decision-making (64.1% vs 42.9%,
p=0.012). No significant difference in the glycaemic
control between the two groups.
Conclusions: Use of the PANDAs decision aid
reduces decisional conflict, improves knowledge,
promotes realistic expectations and autonomy in
people with diabetes making treatment choices in
general practice.
ISRCTN Trials Register Number: 14842077.
ARTICLE SUMMARY
Article focus
▪ Does the use of the PANDAs decision aid in
general practice improve decision quality and
glycaemic control in people who are making
treatment choices about their type 2 diabetes
mellitus (T2DM) treatment, including whether or
not to start insulin?
Key messages
▪ Patient decision aids provide evidence-based
information about treatment options, help
patients to clarify their values and guide them
systematically to make an informed decision.
▪ The use of the PANDAs decision aid by doctors
and nurses in usual NHS general practice with
people who have type 2 diabetes mellitus and
are making treatment choices reduces decision
conflicts and improves knowledge, realistic
expectations and patients’ involvement in
decision-making.
▪ Glycosolated haemoglobin levels were reduced in
both groups at 6 months when compared to
baseline (0.24% controls and 0.37% interven-
tion) with a non-significant mean difference
between the two groups of 0.351, p=0.117.
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INTRODUCTION
Diabetes mellitus is a growing health problem in England
with a total of 2.4 million people (5.5% of population)
living with the disease in 2011.1 Diabetes currently accounts
for 10% of all NHS expenditure.2 However, overall diabetes
control is less than satisfactory. In 2008/2009, 67% of
people with type 2 diabetes mellitus (T2DM) achieved a
glycosolated haemoglobin (HbA1c) of less than 7.5%
(IFCC HbA1c 58 mmol/mol).3
The UK Prospective Diabetes Study (UKPDS) has
established the importance of maintaining good blood
glucose control in patients with T2DM. For every 1.0%
increase in HbA1c, there is an increase, in risk, of 14%
for myocardial infarction, 21% for diabetes-related
deaths and 37% for microvascular complications.4 In the
same study, it was reported that only 25% were able
to achieve good glycaemic control with monotherapy
after 9 years of the trial. Most patients will require
combination therapy, including insulin, 5–10 years after
diagnosis.5
Currently, the NICE guidelines recommend a combin-
ation of metformin and insulin secretagogues in those
who have inadequate blood glucose control with mono-
therapy. For those for whom dual therapy has been
unsuccessful, either insulin or a thiozolidinedione
should be added to optimise glycaemic control.3
Frequently, this poses a clinical dilemma for both
patients and healthcare providers; both parties need to
agree which next treatment option to pursue and this
includes whether or not to start insulin therapy.
However, patients may be fearful of needles and the side
effects of insulin (eg, hypoglycaemia); they need to
acquire new skills; change their daily routine and
address the challenge of glucose monitoring.6 Similarly,
doctors may be hesitant to prescribe insulin due to their
own lack of relevant skills, time pressures and a fear of
increasing the risk of side effects.7 8 In this category of
patients, the decision-making process is a complex one.
Studies have shown that patients usually make decisions
based on emotions such as trust, rather than on the
information given by their healthcare providers.9 For
their part, doctors do not necessarily follow evidence-
based guidelines10 and it was in this context that the
PANDAs decision aid was developed to facilitate shared
decision-making between clinicians and patients when
making decisions about the treatment of their diabetes
at this stage of their illness. The development of the
PANDAs decision aid will be described elsewhere.
Patient decision aids (PDAs) are tools that provide
evidence-based information about treatment options,
help patients to clarify their values and guide them sys-
tematically to make an informed decision. PDAs have
been shown to improve knowledge, realistic expecta-
tions, value-decision concordance and patient involve-
ment in decision-making.11
The primary research question was “Does the use of
the PANDAs decision aid improve decision quality in
patients with T2DM who are making a decision whether
or not to start insulin in general practice?”.
The study focused on people with T2DM who had poor
glycaemic control (HbA1c >7.4 mmol/l or IFCC HbA1c
>57 mmol/mol) and who, despite receiving optimal oral
glucose lowering therapy, required ‘step-up’ treatment.
A cluster randomised controlled trial (RCT) was carried
out to evaluate the clinical effectiveness of the decision
aid on decision quality and glycaemic control.
METHODS
The setting for this study was general practices in
Shefﬁeld, Rotherham and Doncaster with recruitment
being undertaken through the National Institute for
Health Research Primary Care Research Network (PCRN)
and the Cutler Group of South Yorkshire Research
Practices. The recruitment of practices and patients began
in 2008 and the data collection ended in 2011.
Practices were invited to take part by postal invitation fol-
lowing a publicity campaign using a modiﬁed viral market-
ing technique involving sequential non-speciﬁc PANDAs
post cards (‘PANDAs are coming’) to ‘pique’ interest,
followed by increasingly informative ﬂyers (ﬁgure 1).12
The inclusion criteria for general practices were: >4
medical partners; list size >7000; and a diabetes register
with >1% of practice population. The participating
general practices were asked to screen their compu-
terised diabetes register for eligible patients with T2DM
(aged >21 years). The inclusion criteria were: people
with T2DM who were taking at least two oral glucose-
lowering drugs with maximum tolerated dose and had
a latest HbA1c greater than 7.4% (IFCC HbA1c
>57 mmol/mol) or had been advised in the preceeding
6 months to add or consider changing to insulin
therapy. The exclusion criteria were: patients who were
currently using insulin therapy; had difﬁculty reading or
understanding English; had difﬁculty in understanding
the purpose of the study; had visual or cognitive impair-
ment and were mentally ill.
The patients were contacted by a letter from their
general practitioners (GPs) and invited to participate in
this study. If they agreed, they were sent details of the
study (including the information sheet) and asked to
attend an appointment at their regular practice where
ARTICLE SUMMARY
Strengths and limitations of this study
▪ This study was underpowered to detect a minimally, clinically
important difference in glycaemic control between the two
groups due to slow recruitment.
▪ There was no blinding in this study due to the nature of the
intervention which may have influenced the outcome
assessment.
▪ This was a pragmatic trial and there may have been variations
in how the decision aid was used in different general practices
which may have diluted the effect of the study.
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consent to the study was obtained by the researchers.
Practices were incentivised to take part in the trial, receiv-
ing a nominal payment to cover legitimate expenses.
Randomisation and concealment
This was a pragmatic trial and all eligible and willing prac-
tices were randomly allocated by a computer to two
groups: the intervention group used the PANDAs deci-
sion aid when making the speciﬁed treatment choices
and the control group delivered usual care. We stratiﬁed
the practices according to the Practice list size. Each prac-
tice was considered a cluster and all patients within the
cluster received either the intervention or usual care.
The practices were the units of randomisation, since it
would have been difﬁcult to allocate two patients in the
same practice to different arms of the trial. Blinding of
the intervention and assessment of the process measures
were not feasible in view of the nature of the intervention
studied. A statistician generated the random allocation
sequence while a secretary who was not involved in the
research study assigned participants to either the inter-
vention or control groups. A researcher and a research
nurse enrolled the participants into the study.
Intervention and control groups
This was a complex intervention comprising three com-
ponents: PDA; healthcare professional training work-
shop and use of the PDA in a consultation. The
development of the intervention was based on the
UKMRC framework for the development and evaluation
of complex interventions13 and this will be reported in
another paper. The doctors and/or the nurses who were
primarily involved in the diabetes care of the practice
attended a short training session lasting between 1 and
2 h on how to use the PANDAs decision aid. The train-
ing topics covered included the principles of shared
decision-making, the importance and clinical effective-
ness of decision aids, the evidence for various treatment
options for poorly controlled T2DM and essential skills
in risk communication.14
The patient participants were given the PANDAs deci-
sion aid (box 1) by the researcher to read and complete
prior to the consultation in the waiting room. This was
followed by the consultation with the GP or the practice
nurse facilitated by the use of the PANDAs decision aid.
In the control group, the GP and the practice nurse did
not receive any training and the PANDAs decision aid
was not used. The GPs or the nurses conducted a
normal consultation with the patient.
Outcome measures and follow-up
Primary outcome measures
The primary outcome measures were decisional conﬂict
based on the Decisional Conﬂict Scale score,15 16
(immediate) used as an indicator of decision quality and
Box 1 Content of the PANDAs decision aid
The PANDAs decision aid contains the following information in
line with the International Patient Decision Aid Standards criteria:
1. Information about the insulin and other treatment options
▪ Reasons for starting insulin
▪ The procedure of insulin injection
▪ Common concerns about insulin
▪ Treatment options: make no change; lifestyle modification;
insulin therapy
2. Present probablities of outcomes
▪ The advantages and disadvantages of each option were
described in words, numbers and pictures (‘smiley faces’)
3. Patient value clarifications
▪ A list of patients’ values about the advantages and disad-
vantages of insulin therapy
4. Structured guidance
Figure 1 PANDAs postcard: an
example of the viral marketing
strategy to recruit practices.
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glycaemic control (glycosolated haemoglobin, HbA1c)
at 6 months.
Secondary outcome measures
Knowledge and realistic expectations of the risks and
beneﬁts were assessed by asking the patients to indicate
their perceived chance of experiencing the side effects
of insulin therapy and diabetic complications.
Operational deﬁnitions of the secondary outcome
measures were agreed as (1) knowledge: about the treat-
ment option that is most effective in reducing blood
glucose level and diabetic complications; (2) realistic
expectations: a self-reported chance of experiencing
hypoglycaemia, gaining weight and developing compli-
cations; (3) preference option: preferred treatment
options of initiate insulin, adhere to diabetes advice
more regularly or make no change; (4) participation in
decision-making: using the Control Preference Scale
Scores and (5) regret: using the Regret Scale Scores.
The secondary measures were other decision quality
indicators (knowledge of treatment options, realistic
expectation, preference option, proportion undecided,
participation in decision-making); duration of consult-
ation; and outcome of decision-making (regret and
persistence with the chosen option). Persistence with
the chosen option is a single self-reported item which
asked the participant what their treatment was 6 months
after the intervention. They were considered to be per-
sistent with their decision if there was no change in the
treatment in the past 6 months.
The practice provided the baseline and 6-month
follow-up data. Baseline data comprised practice and
clinician proﬁle, patients’ socio-demography, diabetes
proﬁle (duration, complication, prescription, glycaemic
control), comorbidities (eg, hypertension, coronary
artery disease, dyslipidaemia and chronic kidney
disease) and previous T2DM education.
Immediate postintervention data collected were deci-
sion quality indicators and duration of consultation.
Six-month data comprised HbA1c, regret score and per-
sistence with the decision.
Instruments
Decisional Conflict Scale
The Decisional Conﬂict Scale (DCS) measures personal
perceptions of (1) uncertainty in choosing options;
(2) modiﬁable factors contributing to uncertainty such
as feeling uninformed, unclear about personal values
and unsupported in decision-making; and (3) effective
decision-making such as feeling the choice is informed,
value-based, likely to be implemented and expressing satis-
faction with the choice. It was derived from the decisional
conﬂict construct.17 The traditional 16-item DCS with ﬁve
response categories was used in this study. There are ﬁve
subscales: ‘uncertainty subscale’; ‘informed subscale’;
‘values clarity subscale’; ‘support subscale’ and ‘effective
decision subscale’.15 The DCS has been shown to be reli-
able and is correlated with the constructs of knowledge,
regret and discontinuance, and has the ability to discrimin-
ate between those who make and delay decisions. Scores
lower than 25 are associated with implementing decisions
while scores exceeding 37.5 are associated with decisional
delay or feeling unsure about implementation.16
Control Preference Scale
The Control Preference Scale (CPS) aims to measure
the extent to which patients prefer or are involved in
decision-making during a clinical consultation. It mea-
sures the preferred or actual role in decision-making by
asking a single question which contains ﬁve items: two
represent active or patient controlled role; one repre-
sents a shared or collaborative role; and two items repre-
sent a passive or practitioner controlled role.18 It has
proven validity and reliability in both general public and
patients with medical conditions.18 19 A recent study
found a good inter-rater reliability and good agreement
between self and researcher ratings on CPS.20
Regret Scale
This scale measures ‘distress or remorse after a (health-
care) decision’. It is a ﬁve-item scale with ﬁve responses
(1 strongly agree to 5 strongly disagree). Regret is mea-
sured at a point where the respondent can reﬂect on the
effects of the decision that has been made. A score of 0
means no regret while a score of 100 means high regret.
The Regret Scale correlates with satisfaction with the
decision, decisional conﬂict and overall quality of life.21
Sample size and statistical analysis (HbA1c)
Assuming an intracluster correlation coefﬁcient of 0.047
for HbA1c22 and a cluster sample size of 5 patients per
practice, with 80% power and 5% (two-sided) signiﬁ-
cance, 160 patients in each group are required to allow
the detection of 0.5% (SD 1.5%) difference in HbA1c.23
The total number of practices required, therefore, was
estimated to be 64. When using the total DCS score
as the primary outcome measure and using a similar
method to calculate sample size, the total number of
participants needed was 86 and the total cluster size was
estimated to be 17. We aimed for the larger sample size
for the design of this study.
The outcome variables were treated as continuous and
we used multiple regressions with generalised estimating
equations (GEE) and exchangeable correlation to allow
for clustering. Multiple logistic regression with GEE was
used for binary outcomes in the secondary analysis. If a
patient in the intervention arm refused to use the deci-
sion aid, they were still included in the intervention
group for analysis and were analysed according to the
intention-to-treat principle.
RESULTS
Study practices profile
Forty-nine general practices were recruited into the
study. The practices in both arms of the study were well
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matched in terms of mean list size, mean diabetes list
size, mean number of partners and practice nurses and
mean Index of Multiple Deprivation Scores (table 1).
Participants
In total, 182 patients were assessed for eligibility, of
whom seven were excluded for not meeting the inclu-
sion criteria (n=5), or declined to participate (n=2).
A total of 175 patients were randomised, of whom 95
were allocated to the intervention group and 80 to the
control group. Six participants in the intervention group
were lost to follow-up (three died, one moved away and
two withdrew their consent), and two participants in
the control group were also lost to follow-up (one died
and one moved away). The results from 167 participants
were analysed (89 interventions and 78 controls;
ﬁgure 2).24
Table 2 compares the sociodemographic and clinical
proﬁles of patients between intervention and control
groups. The mean age of the patients was 64.6 years
(range 39–87). The patients in the intervention group
and control group were broadly similar except that the
patients in the intervention group were older and more
likely to have coronary heart disease. In both groups the
patients were more likely to consult nurses for diabetes
related conditions than a doctor (mean number of
consultations with nurses and GPs were 2.03 and 1.15,
respectively). The mean length of the initial consult-
ation for patients, when entering the study, in the inter-
vention and control groups was 15.31 and 16.95 min,
respectively (mean difference 1.67 min, 95% CI 0.93 to
4.27 min).
Decisional conflict
The mean difference between the intervention and the
control groups on the total score for decisional conﬂict
was −7.72 (95% CI −12.5 to −2.97). The distribution of
decisional conﬂict subscores are shown in table 3. The
total and subscores for every decisional conﬂict domain,
apart from the support subscore, were signiﬁcantly lower
in the intervention group. The difference in uncertainty,
informed, value clarity and effective decision subscores
between the intervention and control groups remained
Table 1 Study practice profile (mean and range)
Intervention Control
Number of practices 25 24
List size 7510
(3129–20 900)
7325
(1,974–13 500)
People with diabetes 350 (96–912) 356 (143–634)
Number of partners 5 (1–13) 5 (2–10)
Number of practice
nurses
3 (1–6) 3 (1–5)
IMD score 30.35 (range
8.9–59.5)
30.20 (range
6.5–55)
IMD, Index of Multiple Deprivation.
Figure 2 PANDAs CONSORT
flow diagram.
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statistically signiﬁcant after adjusting for differences in
age, education and gender.
Glycosolated haemoglobin
Table 4 shows the HbA1c levels for both the intervention
and the control groups at 6 months. HbA1c levels
reduced in both groups at 6 months compared to base-
line (0.24% in the control group and 0.37% in the inter-
vention group). The mean difference in the HbA1c
level at 6 months between the two groups was 0.351
(95% CI −0.088 to 0.789, p=0.117) after adjusting for
age, education, gender, baseline HbA1c, insulin status
and clustering.
Secondary outcomes
Knowledge
A comparison of the proportions of patients who
answered the ‘knowledge’ questions correctly between
the intervention and the control groups showed there
were more patients in the intervention group who
Table 2 Baseline patient sociodemographic and clinical information of the intervention and control groups (mean and range
unless otherwise stated)
Intervention Control
Sociodemographic profile
Number 95 80
Age (years) 66 (39–82) 62 (42–87)
Male (%) 50 (52%) 46 (57%)
Duration of education (years) (SD) 12.22 (4.83) (8–45*) 11.49 (2.74) (2–22)
Ethnicity white (%) 85 (89.5%) 71 (88.8%)
Clinical profile
Duration of diabetes (years) (SD) 8.4 (4.1) (1–25) 7.07 (3.83) (1–16)
HbA1c (IFCC HbA1c mmol/mol) in past 12 months (%) (SD) 8.6 {70} (1.9) 8.8 {73} (0.98)
(7.4–13.1) {57–120} (7.5–11.5) {58–102}
Number with diabetic complications (%)
Coronary heart disease 29/93 (31.1) 13/80 (16.2)
Peripheral vascular disease 3/93 (3.22) 3/80 (3.75)
Stroke 8/93 (8.6) 5/80 (6.25)
Retinopathy 20/93 (21.5) 10/80 (12.5)
Nephropathy 5/93 (5.37) 10/80 (12.5)
Neuropathy 5/93 (5.37) 3/80 (3.75)
Number with comorbidities (%)
Hypertension 58/93 (62.3) 43/80 (53.75)
Dyslipidaemia 52/93 (55.9) 38/80 (47.5)
Health service utilisation
Number of diabetes-related visits to the general practice in the past
6 months (SD)
General practitioners 0.92 (1.13) (0–5) 1.41 (1.68) (0–11)
Nurse 2.15 (1.84) 1.89 (1.36)
Number of diabetes-related visits to the hospital in the past 6 months (SD) 0.51 (0.87) 0.45 (0.67)
Length of consultation (min) 15.31 (2–39) 16.95 (5–45)
*Self-report (this figure includes self-taught continuing education outwith a formal educational programme).
Table 3 Comparison of decisional conflict scores between the intervention and control groups (0=no decisional conflict,
100=maximum decisional conflict)
Subscore Intervention Control
Mean difference
unadjusted
Mean difference
adjusted* 95% CI, p Value
Uncertainty 20.1 (16.6) 29.4 (20.8) −9.29 −8.72 −14.9 to −2.53, p=0.006
Informed 18.1 (13.3) 26.0 (16.6) −7.65 −8.69 −13.3 to −4.10, p<0.001
Values clarity 16.7 (13.9) 26.7 (18.2) −9.74 −9.84 −14.8 to −4.84, p<0.001
Support 17.4 (13.1) 20.8 (15.3) −3.41 −3.66 −8.58 to 1.25, p=0.144
Effective decision 16.1 (14.4) 23.3 (15.2) −9.70 −9.80 −16.8 to 2.75, p=0.006
Total score 17.4 (12.6) 25.2 (14.9) −7.67 −7.72 −12.5 to −2.97, p<0.001
*Adjusted for clustering, insulin initiation, age, gender and education level.
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answered the questions correctly compared to those who
received ‘usual care’ (table 5).
Realistic expectations
Patients who used the decision aid had signiﬁcantly more
realistic expectations about the side effects of insulin
therapy compared to those who did not (table 5). Almost
all patients in the intervention group, compared to those
of the control group, knew correctly their risk of hypogly-
caemia (81% vs 5.2%, p<0.001) and weight gain (70.5%
vs 5.3%, p<0.0010). More people knew their risk of com-
plications in the intervention group if they were to take
insulin, although most still got it wrong (26.3% vs 5.0%,
p<0.001).
Preferred option
Table 6 shows that the preferred choices of patients in
the intervention and control groups were similar after
consultation.
Proportion undecided
Table 7 shows that patients in the intervention group
were over three times more likely to change from
undecided to decided than in the control group,
although, this was not statistically signiﬁcant (p=0.15).
Participation in decision-making
There were signiﬁcant differences in patients’ decision-
making role between the intervention and control
groups (p=0.012 χ2; table 8). It may be seen that a
smaller proportion of patients in the intervention group
described their decision about their diabetes treatment
as ‘passive’ or ‘collaborative’.
However, patients in the intervention arm were more
likely to demonstrate autonomy in their decision-making
about their treatment compared to the control group
(64% compared to 43%). Further analysis showed that
an individual patient was 1.23 (95% CI 1.05 to 1.44,
p=0.008) times more likely to make an ‘autonomous’
decision using the PANDAs decision aid when the inter-
vention and control groups are compared, allowing for
age and gender.
Regret and persistence with decision
Table 9 shows that there was no difference at 6 months
in the Regret Scale, but that patients in the intervention
group were rather more likely to persist with their
chosen option.
Acceptability
Most of the PDA users found the PDA useful. When
asked about their opinion of the PDA, 83.2% (n=88),
86.3% (n=89), 86.3% (n=89) and 88.4% (n=90) thought
that the PDA had helped them to recognise that a deci-
sion needs to be made; know that the decision depends
Table 5 Secondary outcomes: knowledge and realistic expectations (questions answered correctly)
Intervention
decision aid
Control usual
care
Unadjusted
OR
Adjusted* OR
(95% CI) ICC p Value
Knowledge
Number 95 80
Which choice has the greatest chance
of lowering your blood sugar?
49 (51.6%) 23 (28.8%) 2.63 1.31
(1.14 to 1.50)
0.071 <0.001
Which choice has the greatest chance
of lowering your complications?
29 (30.5%) 23 (28.8%) 1.09 1.20
(0.07 to 19.05)
0.202 0.90
Realistic expectations
If you take insulin, about how many
times might you experience ‘hypos’
in a year?
77/95 (81.0%) 4/75 (5.2%) 75.9 † – <0.001‡
If you take insulin, about how much
more weight might you gain in a year?
67/95 (70.5%) 4/75 (5.3%) 42.5 † – <0.001‡
Out of 100 people like you who take
insulin, how many may get
complications in 5 years?
25/95 (26.3%) 4/80 (5%) 6.8 † – <0.001‡
*Adjusted for clustering, insulin initiation, age, gender and education level.
†Numbers answering correctly in the control group were too few to control for clustering.
‡χ2 p value.
Table 4 Effect of the PANDAs decision aid on HbA1c
at 6 months
Intervention Control
Mean
difference
in HbA1c
unadjusted
Mean
difference
in HbA1c
adjusted* 95% CI
8.64 (SD
1.37)
8.40
(SD
1.31)
0.244 0.351 −0.088
to
0.789
*Adjusted for age, education, gender, baseline HbA1c, insulin
status and clustering. p=0.117.
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on what matters most to them; think about how involved
they wanted to be in the decision; and prepare to talk to
the nurse or doctor about what mattered most to them’,
respectively.
DISCUSSION
The PANDAs decision aid was designed to facilitate
decision-making between clinicians and their patients
with T2DM who were taking at least two oral glucose-
lowering drugs at maximum tolerated dose, had a high
HbA1c level and were considering future treatment
options including the introduction of insulin. Its evalu-
ation was based on the International Patient Decision
Aids Standards (IPDAS) recommendations25 and the
use of the ODSF Framework.26 The PANDAs trial pro-
vides good evidence not only for the clinical effective-
ness of decision aids in usual NHS general practice but
also for the utility and feasibility of use by both nurses
and doctors. In addition, the PANDAs decision aid itself
and its use were both effective and acceptable to people
with diabetes making treatment choices during clinical
consultations.
Decision quality
The ﬁndings from the PANDAs trial support the results
of other studies which have evaluated the clinical effect-
iveness of decision aids11 15 in demonstrating an
improvement in decision quality when a decision aid is
used in clinical consultations.
Decisional conﬂict scores, for example, when adjusted
for age, education and gender were signiﬁcantly lower
in the intervention group postconsultation when com-
pared to the controls, apart from the support subscore.
It is interesting to note that the support subscore in the
intervention group was not signiﬁcantly lower than the
control group—this may be the result of a ‘ceiling
effect’ since patients in both the intervention and
control groups may already have been receiving very
good diabetes care from their general practices.
Other indicators of decision quality used in the study
also demonstrated an improvement when PANDAs was
used in consultations—there was, for example, a highly
signiﬁcant difference in the knowledge of people about
which particular treatment choice had the greatest chance
of lowering blood sugar in those who used the decision
aid—although this was not the case when the chance of
insulin in lowering complications was considered—here no
difference in knowledge was observed. Some patients
believe that insulin itself causes complications as a result of
misperception27 28 and this may explain why knowledge
did not improve in the intervention group. However, highly
signiﬁcant differences were observed between the interven-
tion and control groups in all the three domains of realistic
expectations (‘hypos’, weight gain and complications) sup-
porting the notion that the PANDAs decision aid ensured
that people were fully informed about the potential risks of
each option when making their treatment choices.
As far as autonomy was concerned, patients in the inter-
vention arm were more likely to make an autonomous deci-
sion using PANDAs when the intervention and control
groups were compared allowing for both age and gender.
This is consistent with the ﬁndings of other studies.29 30
These ﬁndings of an improvement in decision quality,
when a decision aid is used in clinical consultations in
other conditions and contexts, are also supported by a
large number of other studies.23 31
Decisional outcomes
The glycaemic control improved in both groups 6
months after the intervention although no signiﬁcant
Table 7 Comparison of the proportion of patients who
remained undecided between the intervention and control
group immediately after intervention
Intervention Control OR 95% CI
Undecided
(preconsultation)
23 14
Undecided
(postconsultation)
8* 9*
Odds in favour of
changing:
undecided (pre) to
decided (post)/
decided (pre) to
undecided (post)
18/3† 11/6† 3.27 0.69 to
16.3
(p=0.15)
*This figure of eight patients includes five who remained
‘undecided’ postconsultation and includes three patients who
moved from ‘decided’ preconsultation to ‘undecided’
postconsultation. Similarly for the nine ‘undecided’
postconsultation patients in the control group, three remained
‘undecided’ and six had moved from ‘decided’ to ‘undecided’.
†This ratio means that a total of 18 patients changed from
‘undecided’ to ‘decided’ in the intervention group and that 3 moved
in the opposite direction (ie, a net total of 15 patients (18–3) had
‘decided’ postconsultation). In the control group the corresponding
numbers were 11 and 6 (ie, a net total of 5 patients (11–6) had
‘decided’ postconsultation).
Table 6 Preferred choices of patients in intervention and control groups postconsultation
Make no change
Follow the diabetes
advice more regularly Start insulin I am not sure Total
Control 33 (42.4%) 29 (37.1%) 9 (11.5%) 7 (9%) 78
Intervention 32 (34.8%) 38 (41.3%) 17 (18.5%) 5 (5.4%) 92
Total 65 67 26 12 170
(χ23=2.88, p=0.410).
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difference in glycaemic control was observed between
the two groups. Some GPs in the study expressed
concern at the start of the trial that glycaemic control
could deteriorate in some patients in the intervention
group as a result of them choosing not to start insulin.
Further study is necessary to conﬁrm this as this study
did not have sufﬁcient power to detect the difference in
glycaemic control.
Treatment decisions made using a decision aid should,
of course, be ones that are both informed and value-
based, and the PANDAs intervention was focused on the
process of decision-making rather than the outcomes of
those decisions. It is therefore important to note that
PANDAs was not designed to persuade people to start
treatment with insulin but to help them make an
informed treatment decision which was consistent with
their values and wishes.
Indeed, there was reduced decisional conﬂict within
the intervention group compared to the control and the
decisions which were made were far more likely to be
autonomous in nature rather than passive. Participants in
the intervention group were also signiﬁcantly more likely
to persist with their chosen option at 6 months. This sup-
ports the hypothesis that people who use a decision aid
such as PANDAs are more likely to make an informed
and value-based decision and are therefore more likely
to persist with their treatment choice. Concordance with
agreed treatment is, in turn, more likely to lead to better
health outcomes and quality of life.
No signiﬁcant difference was observed on the Regret
Scale scores and although people in the intervention
group were over three times more likely to change from
undecided to decided (ie, come to a treatment decision
after their consultation) in the control group, this differ-
ence was not statistically signiﬁcant.
Finally, no signiﬁcant difference was observed in the
preferred choices (ie, the treatment decision they came
to) of the two groups although a higher proportion of
people in the intervention group did choose to initiate
insulin. However it is important to note that the use of a
decision aid is not intended to produce a particular
outcome but to support the patient making a treatment
choice based on their knowledge and values. These ﬁnd-
ings are also consistent with current understanding of
the anticipated decisional outcomes when a decision aid
such as PANDAs is used in clinical consultations to make
treatment choices.31
Impact on clinical practice
The results of the PANDAs trial demonstrate that the
use of the decision aid in usual general practice by both
practice nurses and GPs, provided the patient has the
opportunity to complete their individualised decision
aid prior to their consultation, does not require signiﬁ-
cant additional consultation time. Given the potential
beneﬁts of improved adherence to treatment choices
and an improved therapeutic relationship between clini-
cians and their patients, this is likely to make the use of
the decision aid acceptable to all parties in general prac-
tice, although, its use may require some initial ‘invest-
ment’ in consultation time. In particular, both clinician
and patient satisfaction with their consultations, as well
as the healthcare provided and received, are both likely
to be increased. A further potential advantage is that the
decision aid could be used by other clinical members of
the primary care team (eg, healthcare assistants) poten-
tially increasing the consultation time available to
doctors and nurses for other patients. However, the efﬁ-
cient use of the decision aid in consultations may in part
be attributed to the familiarity of the clinicians with the
decision aid as a result of the brief training clinicians
received at entry to the trial. In addition, this may also
be due to the process by which the decision aid was
developed with the active involvement of both clinicians
Table 9 Comparison of the decision Regret Score and persistence with chosen option between the intervention and usual
care groups after 6 months
Intervention Control
Mean difference
unadjusted
Mean difference
adjusted* p Value
Regret Score 44.63 44.57 0.06 0.22 (−2.48 to 2.93) 0.872
Persistence with chosen option 68.1% 56.3% 1.65† 1.17‡ (1.00 to 1.36) 0.041
*Adjusted for age, education, gender, baseline HbA1c, insulin status and clustering.
†Crude OR.
‡Adjusted OR.
Table 8 Decision-making roles of patients in the intervention and control groups, postconsultation with their doctor/nurse
How did you make your decision about your diabetes treatment? (n=169)
Passive Collaborative Autonomous Total
Control 16 (21%) 28 (36%) 33 (43%) 77 (100%)
Intervention 8 (9%) 25 (27%) 59 (64%) 92 (100%)
(χ2=8.9, df=2, p=0.012).
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and people with diabetes to ensure that it was as ‘user
friendly’ as possible. This involvement of users in the
development of the decision aid and a process evalu-
ation of its use in the consultation by both parties has
been described elsewhere.32
Health service utilisation
The PANDAs trial was a pragmatic one reﬂecting the
reality of primary care diabetes clinics which are mainly
run by practice nurses. The mean number of consulta-
tions with the nurses, for example, was greater than the
mean number of consultations with the GPs and within
the intervention group patients were more likely to use
the PANDAs decision aid with the practice nurse than
the GP. At baseline the distribution of the mean number
of diabetes related general practice visits was different in
the intervention and control groups with the practice
nurses providing more clinical care to people with dia-
betes in the former reﬂecting different patterns of care
in the different practices.
Patient decision aids
The PANDAs decision aid is one of the few decision aids
which focus on decision-making in chronic diseases,
which take place over several consultations. According to
the latest Cochrane Decision Aid Inventory, 10 decision
aids have been developed for diabetes.31 Four decision
aids focus on insulin treatment, of which two are for
children, one for adults deciding on premixed insulin
and one for insulin initiation in T2DM (PANDAs deci-
sion aid). However, unlike PANDAs, none have been
developed for making treatment decisions about gly-
caemic control.
Although decision aids have positive effects on many
aspects of the decision-making process, there remains a
large gap in the literature on how decision aids fare ‘in
the real world’. O’Cathain and Thomas33 conducted a
pragmatic trial of a decision aid in a maternity ward and
found that health professionals were not making use of
the available decision aids, although they reported that
they approved of them. The reasons for not using them
included ‘disagreement’ with the available decision aids,
lack of resources, perceived patients’ reluctance to par-
ticipate and unwillingness to change their ‘routine
care’.33 O’Donnell et al34 classiﬁed the barriers to the
use of decision aids in the clinical situation under three
categories—the nature of the decision aid itself, the atti-
tudes of patients and healthcare professionals and
organisational barriers such as institutional culture and
commitment, time constraint and costing.
A number of authors have proposed various strategies
to facilitate such use of decision aids in different clinical
settings.35 The effectiveness of these proposed strategies
has not yet been formally evaluated. The PANDAs trial
however found the decision aid to be highly acceptable
to both clinicians and people with diabetes in NHS
general practice—a detailed process evaluation of its use
can be found elsewhere. This report identiﬁes some of
the key challenges to its widespread implementation in
NHS general practice.
However, most studies of decision aids have not shown
an increase in the level of satisfaction with the decision-
making process or the decision itself. This may be
another example of the ‘ceiling effect’ whereby the satis-
faction with the service or consultation was already high
before the intervention. It has also been observed that
people tend to report satisfaction after they have made
the decisions because they tend to ‘rationalise’ and adapt
quickly to uncertain events.36 Moreover, the effect of
decision aids on quality of life and health outcomes indi-
cators which are commonly used in health technology
assessments, have yet to be proved. More plausible inter-
mediate outcomes, such as concordance with treatment
and health service utilisation, could be used as alternative
indicators to evaluate the use of decision aids.
General practice is a unique healthcare setting where
multidisciplinary teams provide holistic, comprehensive
and continuity of care to people in the community.
Practitioners usually have an established relationship with
their patient and an appreciation of their medical and psy-
chosocial background as well as their associated multimor-
bid conditions. This puts them in a very good position to
advise patients on their treatment options. The use of deci-
sion aids to facilitate treatment choices in general practice
ﬁts well with the adoption of a Care Planning model for
long-term conditions. This model of care, developed by
the Diabetes UK Year of Care Programme and recently
adopted as a professional standard by the Royal College of
General Practitioners (RCGP), is a good way of ensuring
that patients with diabetes are both fully informed and
fully involved in decisions about their care by supporting
their ‘empowerment’ and facilitating the ‘activation’ of
people with long-term conditions.37 38
Implications for research and clinical practice
For the use of PDAs, such as PANDAs, in routine clinical
practice to become the accepted norm, the new GP clin-
ical commissioning groups will need to be aware of the
beneﬁts of the use of such aids to ensure that decision
aids become a professional standard in, for example,
newly commissioned pathways for a long-term condition
such as diabetes. Investment will also be necessary for
the development and the continuing evaluation of deci-
sion aid use, as well as for the training of all members of
the multidisciplinary team in the importance and in the
practical use of decision aids in primary care. Both the
patient’s experience and patient/clinician satisfaction
with the care received and provided is likely to be much
improved if this professional standard is adopted by
commissioning groups.
CONCLUSIONS
The use of the PANDAs decision aid by healthcare pro-
fessionals in usual NHS clinical practice with T2DM
patients who are making treatment choices in general
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practice improves decision quality by reducing decisional
conﬂict, improving knowledge and promoting realistic
expectations but has no demonstrable effect on gly-
caemic control.
Patient autonomy however is strengthened by the use
of the decision aid and longer term clinical outcomes
are likely to be improved. A larger trial of the PANDAs
decision aid will be necessary to determine if biomedical
parameters are improved when the decision aid is used
in normal NHS practice.
STRENGTHS AND LIMITATIONS OF THIS STUDY
The study failed to achieve its planned sample size as a
result of recruitment difﬁculties. The reasons for this
were the increase in availability of new oral and inject-
able glucose-lowering drugs (eg, GLP1 agonosts, exena-
tide) which were not available at the start of the project,
signiﬁcant staff changes in 2008/2009 and the reluc-
tance of practices to participate in the study because of
a potential H1N1 ﬂu pandemic in summer 2009. As a
result each practice was only able to identify 3–5 eligible
patients for inclusion in the trial. It proved impossible to
secure a funded time-extension to the study and as a
result recruitment ceased at 175 participants. This
meant that the study was underpowered to detect a dif-
ference of 0.5% in HbA1c between the two groups. The
original recruitment period was 12 months but because
of the problems surrounding recruitment outlined
above, recruitment was extended to 20 months. There
was also some evidence of inadvertent recruitment bias
with 95 participants allocated to the intervention group
and 80 to the control group. This is an important and
well-recognised consequence of a cluster RCT design
and is probably the result of the PANDAs practices
being more likely to recruit participants to the trial.
There were some differences in baseline characteristics
between the intervention and the control and these
were included in an analysis which explored how the
estimates of the treatment effect changed when baseline
differences were controlled for.
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